Shiho Makabe1, Toshio Mochizuki1, Michihiro Mitobe1, Yumi Aoyama1, Hiroshi Kataoka1, Ken Tsuchiya1, Kosaku Nitta2. 1. Department of Internal Medicine, Kidney Center, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan. 2. Department of Internal Medicine, Kidney Center, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan. knitta@twmu.ac.jp.
Abstract
BACKGROUND: In 2014, tolvaptan, a vasopressin receptor antagonist, was approved for the treatment of autosomal dominant polycystic kidney disease (ADPKD) in Japan. Clinical trials of tolvaptan revealed frequent occurrence of the liver function abnormality. According to the package insert in Japan, liver function tests should be performed once a month in patients receiving tolvaptan. Furthermore, immediate discontinuation of tolvaptan is recommended in the appearance of liver function abnormalities. METHODS: Seven patients of ADPKD who was discontinued tolvaptan because of elevation of the serum liver enzyme levels were described in detail and analyzed. RESULTS: None of them fulfilled the criteria for applicability of Hy's law, which predicts a high risk of severe, potentially fatal, drug-induced liver injury (DILI). In our patients, the rate of increase of total kidney volume (TKV) significantly decreased during tolvaptan administration, but increased after discontinuation; in Cases 1-5, mean annual growth rate of TKV during administration was - 10.15%/year, and during discontinuation was + 23.72%/year. After the serum liver enzyme levels returned to normal range, tolvaptan was resumed in six patients with informed consent. Except one patient, tolvaptan has been continued without increase of the serum liver enzyme levels. CONCLUSION: In patients with mild elevation of the serum liver enzyme, as is less than three times the upper limit of normal (ULN), resumption of tolvaptan may be considered after the serum liver enzyme levels return to normal range.
BACKGROUND: In 2014, tolvaptan, a vasopressin receptor antagonist, was approved for the treatment of autosomal dominant polycystic kidney disease (ADPKD) in Japan. Clinical trials of tolvaptan revealed frequent occurrence of the liver function abnormality. According to the package insert in Japan, liver function tests should be performed once a month in patients receiving tolvaptan. Furthermore, immediate discontinuation of tolvaptan is recommended in the appearance of liver function abnormalities. METHODS: Seven patients of ADPKD who was discontinued tolvaptan because of elevation of the serum liver enzyme levels were described in detail and analyzed. RESULTS: None of them fulfilled the criteria for applicability of Hy's law, which predicts a high risk of severe, potentially fatal, drug-induced liver injury (DILI). In our patients, the rate of increase of total kidney volume (TKV) significantly decreased during tolvaptan administration, but increased after discontinuation; in Cases 1-5, mean annual growth rate of TKV during administration was - 10.15%/year, and during discontinuation was + 23.72%/year. After the serum liver enzyme levels returned to normal range, tolvaptan was resumed in six patients with informed consent. Except one patient, tolvaptan has been continued without increase of the serum liver enzyme levels. CONCLUSION: In patients with mild elevation of the serum liver enzyme, as is less than three times the upper limit of normal (ULN), resumption of tolvaptan may be considered after the serum liver enzyme levels return to normal range.
Authors: Jeffrey L Woodhead; Paul B Watkins; Brett A Howell; Scott Q Siler; Lisl K M Shoda Journal: Drug Metab Pharmacokinet Date: 2016-11-21 Impact factor: 3.614
Authors: Merrie Mosedale; Yunjung Kim; William J Brock; Sharin E Roth; Tim Wiltshire; J Scott Eaddy; Gregory R Keele; Robert W Corty; Yuying Xie; William Valdar; Paul B Watkins Journal: Toxicol Sci Date: 2017-04-01 Impact factor: 4.849
Authors: Vicente E Torres; Arlene B Chapman; Olivier Devuyst; Ron T Gansevoort; Jared J Grantham; Eiji Higashihara; Ronald D Perrone; Holly B Krasa; John Ouyang; Frank S Czerwiec Journal: N Engl J Med Date: 2012-11-03 Impact factor: 91.245
Authors: Jason R Slizgi; Yang Lu; Kenneth R Brouwer; Robert L St Claire; Kimberly M Freeman; Maxwell Pan; William J Brock; Kim L R Brouwer Journal: Toxicol Sci Date: 2015-10-26 Impact factor: 4.849
Authors: Paul B Watkins; James H Lewis; Neil Kaplowitz; David H Alpers; Jaime D Blais; Dan M Smotzer; Holly Krasa; John Ouyang; Vicente E Torres; Frank S Czerwiec; Christopher A Zimmer Journal: Drug Saf Date: 2015-11 Impact factor: 5.606
Authors: Jeffrey L Woodhead; William J Brock; Sharin E Roth; Susan E Shoaf; Kim L R Brouwer; Rachel Church; Tom N Grammatopoulos; Linsey Stiles; Scott Q Siler; Brett A Howell; Merrie Mosedale; Paul B Watkins; Lisl K M Shoda Journal: Toxicol Sci Date: 2016-09-21 Impact factor: 4.849